Major pharmaceutical firms' consumer health business sales growth in the latest quarter was put on the back burner among indicators for each one's outlook as the potential for some of the businesses changing owners fuels growing speculation.
Merck KGAAignited the discussion in September with its announcement that it is looking at selling its division marketing Nasivin OTC saline nasal sprays, Omnibionta probiotic vitamins and other brands, and Pfizer Inc